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Abstract
We report a case of P. aeruginosa cholangitis in an adult with cystic fibrosis (CF). The patient had a past history of
cholecystectomy and a new finding of intrahepatic biliary duct stricture. Evaluation and treatment with endoscopic retrograde
cholangiopancreatography (ERCP) and percutaneous biliary tract drainage was complicated by post-procedure pain and fever.
The only organism recovered from biliary drainage was P. aeruginosa. Southern blot analysis of respiratory and biliary cultures
confirmed that the isolates were identical. Despite aggressive antibiotic therapy and drainage, persistent cholangitis and infection
have not been eradicated after 6 months. The most likely mechanism of infection of the biliary tract was direct introduction of
the upper respiratory tract pathogen during the diagnostic procedure.  2002 European Cystic Fibrosis Society. Published by
Elsevier Science B.V. All rights reserved.
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1. Introduction
CF is the most common, fatal heritable condition in
the Caucasian population. While the major cause of
morbidity and mortality is chronic lung infection with
P. aeruginosa and respiratory failure, hepatobiliary dis-
ease is a common co-morbidity. More than 50% of adult
CF patients have evidence of cholelithiasis or other gall
bladder pathology, and approximately 1.6% of CF
patients die from hepatobiliary complications of CF w1x.
Biliary tract infection is an uncommon event in CF. We
report a case that has proven refractory to therapy, in
which the upper respiratory tract was confirmed as the
source of infection of the biliary system with P. aeru-
ginosa following ERCP.
2. Case report
A 26-year-old white male with CF diagnosed at 4
years of age by sweat chloride testing was admitted to
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the hospital for evaluation of chronic abdominal pain.
The patient noted mid-epigastric abdominal pain, waxing
and waning in nature, with associated anorexia, transient
fever and a 30-lb. weight loss over the 5 months prior
to admission. He denied nausea, vomiting or increased
pain post prandially. Outpatient evaluation, including an
abdominal ultrasound and upper gastrointestinal endos-
copy, was unremarkable. Abdominal computerized
tomography (CT) imaging prior to admission revealed
intrahepatic ductal dilatation in the left hepatic lobe.
Past medical history included pancreatic insufficiency.
Spirometry revealed moderate airflow obstruction with
an FEV of 2.04 l (42% of predicted) and a FVC of1
3.30 l (56% of predicted). Mucoid and non-mucoid P.
aeruginosa was cultured from the sputum over the
previous 11 years. The patient’s most recent hospitali-
zation for a CF exacerbation was 2 years prior to
admission. Surgical history was significant for cholecys-
tectomy 7 years previously. Outpatient medications
included pancreolipase and oxycontin. Examination at
the time of admission revealed decreased oxygen satu-
ration, cachexia, rhonchorus breath sounds and mid-
epigastric abdominal pain without rebound or guarding.
The patient was afebrile; neither hepatosplenomegaly
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Fig. 1. Cholangiogram demonstrating multiple strictures in the hepa-
tobiliary system and common bile duct (black arrows). Both external
and internal drains are present.
Fig. 2. DNA analysis of P. aeruginosa by southern blot reveals iden-
tical strains in lanes 2–4. Lane 1: Control P. aeruginosa, Lane 2:
Sputum isolate, Lane 3: Bile isolate from New Mexico, Lane 4: Bile
drain isolate from Colorado.
nor ascites were appreciated. Laboratory studies dem-
onstrated a total bilirubin of 1.4 mgydl, alkaline phos-
phatase of 492 Uyl, normal transaminases, lipase of -
1 Uyl and total leukocyte count of 5.6=10 cells.3
The patient was admitted to the hospital and treated
with narcotics and famotidine (20 mg i.v. b.i.d.). On
hospital day 5, a tight, common bile-duct stricture was
found on ERCP. Contrast was not visualized distal to
the obstruction and the pancreatic duct could not be
cannulated. Percutaneous cholangiogram and biliary
drainage completed on hospital day 12 demonstrated a
long stricture in the common bile duct with high-grade
stenosis and concomitant distal stricture (Fig. 1). On
hospital day 15, the patient suffered from worsening
abdominal pain with concomitant fever. Cultures of the
bile fluid obtained at the time of biliary drainage noted
Gram-negative rods that were identified as P. aerugino-
sa. The patient was begun on anti-pseudomonal antibi-
otics in addition to bilateral internalyexternal biliary
drainage; he gradually improved and was discharged on
hospital day 35. Subsequent sampling of the biliary
stricture by brushing and biopsy ruled out cholangiocar-
cinoma, but identified mucoid bile and intrahepatic
cholelithiasis that was successfully treated endoscopic-
ally. However, in the 6-month follow-up period to date,
the patient has continued to suffer from symptomatic
cholangitis with only transient improvement on anti-
pseudomonal antibiotics. Culture from biliary drainage
persistently demonstrates P. aerugninosa.
During the hospitalization, mucoid P. aeruginosa was
the single pathogen isolated from the patient’s sputum.
DNA analysis by Southern blot from the biliary drainage
and sputum revealed identical strains (Fig. 2). The three
isolates of P. aeruginosa, along with an epidemiologi-
cally unrelated control organism, were characterized by
pulsed-field electrophoresis. Chromosomal DNA was
digested with XbaI, and then fragments were separated
on a 1% Seakem agarose gel using a CHEF DRII
apparatus (BioRad, Richmond, CA). Macrorestriction
fragments were visually compared and interpreted
according to standard criteria w2x.
3. Discussion
The case presented describes the first documentation
that chronic biliary tract infection following ERCP in
CF can result from inoculation with the mucoid respi-
ratory tract strain of P. aeruginosa. CF patients suffer
from multiple hepatobiliary complications. Although the
pathogenesis of CF associated liver disease is not com-
pletely understood, the ultimate result is impaired secre-
tory function of the biliary epithelium, producing
cholestasis and leading to portal fibrosis. The course of
this process leads to progressive liver fibrosis and
cirrhosis w3,4x. The clinical abnormalities of hepatome-
galy, persistently elevated liver function tests and ultra-
sonographic abnormalities are noted in 13–17% of
patients w3,4x. Cholelithiasis and micro-gall-bladder dis-
ease is observed in approximately 50% of patients, with
cholecystitis occurring in 1–10% of patients w3–5x.
Common bile-duct stenosis, as noted in our patient,
occurs rarely and less frequently than intrahepatic ductal
stenosis w6x.
Despite the high incidence of biliary tract disease in
CF, cholangitis is relatively uncommon. However, post-
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ERCP cholangitis has been associated with P. aerugi-
nosa infection in the non-CF setting. Novello et al.
studied 2010 patients completing ERCP to identify the
risk of infectious complications. Cholangitis developed
in 2.5% of patients completing ERCP; P. aeruginosa
was the most common agent, found in 30% of cases
w7x. Rodriguez et al. found P. aeruginosa cholangitis
complicating ERCP in 3.6% of cases over a 4-year
period w8x. Novello et al. identified four risk factors for
post-ERCP infection: (1) complete biliary obstruction;
(2) multiple cannulation attempts; (3) malignant biliary
obstruction; and (4) incomplete drainage after ERCP
w7x.
As in this patient, CF patients are often colonized
with P. aeruginosa. Evidence suggests that chronic
airway colonization occurs in most patients by age 15
w9x. In addition to colonization of the lung, P. aeruginosa
isolates have been reported in stool cultures of CF
patients. Reported rates of fecal carriage of P. aeruginosa
vary from less than 10% in healthy subjects to greater
than 40% in hospitalized patients w10x. In addition,
Agnarsson et al. reported identical isolates of P. aeru-
ginosa from the lung and stool in 8 out of 10 patients
with CF, suggesting a considerable degree of intestinal
contamination with mucoid P. aeruginosa from the
respiratory tract w10x. However, to the best of our
knowledge there have been no reports of lung coloni-
zation and cholangitis with identical P. aeruginosa
strains in CF patients.
It is most likely that the P. aeruginosa isolated from
this patient’s biliary tract was inoculated onto the endo-
scope during passage through the oropharynx, as naso-
pharyngeal cultures generally demonstrate a similar
pattern of infection to sputum cultures in CF patients
w9x. It is also possible that the organism had colonized
the patient’s upper gastrointestinal tract, particularly
given the use of H -blocker, which might increase the2
survivability of mucoid P. aeruginosa. A particularly
disturbing feature of this case was the inability to
eradicate the infection. Multiple mechanisms in the lung
result in an inability to eradicate pulmonary mucoid P.
aeruginosa. One of the most important mechanisms is
biofilm formation by the organism. Biofilm is a com-
plex, multi-organism community encased in a mucopol-
ysaccharide, alginate matrix w11x. Mucoid organisms are
particularly resistant to both intrinsic host defense mol-
ecules and medically administered antibiotics. Our case
suggests the possibility that mucoid P. aeruginosa may
be a more difficult organism to eradicate once it colo-
nizes the biliary tract in CF patients as well. Thus, it
may be advisable to use particular caution when consid-
ering ERCP in CF patients colonized with mucoid P.
aeruginosa. A potential alternative imaging modality of
the biliary system is the non-invasive magnetic reso-
nance cholangiopancreatography (MRCP), which has
been utilized in CF patients to determine the presence
and severity of biliary complications. Perez-Aguilar et
al. reported that MRCP detected hepatobiliary disease
in 100% of CF patients previously diagnosed with liver
disease and revealed bile duct anomalies in five patients
without previous diagnosis of liver disease. Of note,
ductal lesions not detected by ultrasound were visible
by MRCP w12x. MRCP provides the ability to distinguish
between intra- and extrahepatic manifestions and may
provide an appropriate non-invasive alternative to ERCP
for diagnosis of hepatobiliary disease in CF patients
colonized with mucoid P. aeruginosa.
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